David Ricks, chief executive officer of Eli Lilly & Co., at the Semafor World Economy Summit during the International Monetary Fund (IM...

The FDA authorized Eli Lilly's drug as part of a new program aimed at cutting drug approval times

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz mon...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

European Association for the Study of Obesity says the drugs are so effective, they should be used for almost all obesity patients

By Naomi Kresge | BloombergEli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nord...

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s d...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head...

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs, Mounjaro and...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance.Related ArticlesHealth |...